IMMUNOASSAYS FOR THE DETECTION OF UROKINASE RECEPTOR FORMS

Timo Piironen; Gunilla Hoeyer-Hansen,; Nils Bruenner,; Michael Ploug,; Karin List; Birgitte Laursen,; Keld Danoe,; Hans Liljas,; Alexander Haese; Huland Hartwig,; Magnus Toernblom,; Ove Gustafsson,

IMMUNOASSAYS FOR THE DETECTION OF UROKINASE RECEPTOR FORMS

Timo Piironen (Inventor), Gunilla Hoeyer-Hansen, (Inventor), Nils Bruenner, (Inventor), Michael Ploug, (Inventor), Karin List (Inventor), Birgitte Laursen, (Inventor), Keld Danoe, (Inventor), Hans Liljas, (Inventor), Alexander Haese (Inventor), Huland Hartwig, (Inventor), Magnus Toernblom, (Inventor), Ove Gustafsson, (Inventor)

Abstract

The present invention relates to the design of three novel monoclonal uPAR sandwich assays for the specific detection of 1) full-length intact uPAR, 2) full-length intact uPAR and domain 2+3 fragment, and 3) domain 1 fragment of uPAR. The invention further relates to a method combining the detected amounts of uPAR forms in a sample with data indicative of the presence of the cancer disease. The method can be used for staging, prognosis or diagnosis of prostate cancer. Two novel monoclonal antibodies and a kit and immunoassays for detecting at least one uPAR form(s) are also described in the present invention.

Original language	English
IPC	G06F 19/ 20 A N
Patent number	WO2004099780
Country/Territory	Denmark
Priority date	06/05/2003
Priority number	DK20030000676
Publication status	Published - 18 Nov 2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@misc{0315637c93ba46f28800e35b1a9b1ea2,

title = "IMMUNOASSAYS FOR THE DETECTION OF UROKINASE RECEPTOR FORMS",

abstract = "The present invention relates to the design of three novel monoclonal uPAR sandwich assays for the specific detection of 1) full-length intact uPAR, 2) full-length intact uPAR and domain 2+3 fragment, and 3) domain 1 fragment of uPAR. The invention further relates to a method combining the detected amounts of uPAR forms in a sample with data indicative of the presence of the cancer disease. The method can be used for staging, prognosis or diagnosis of prostate cancer. Two novel monoclonal antibodies and a kit and immunoassays for detecting at least one uPAR form(s) are also described in the present invention.",

author = "Timo Piironen and Gunilla Hoeyer-Hansen, and Nils Bruenner, and Michael Ploug, and Karin List and Birgitte Laursen, and Keld Danoe, and Hans Liljas, and Alexander Haese and Huland Hartwig, and Magnus Toernblom, and Ove Gustafsson,",

year = "2004",

month = nov,

day = "18",

language = "English",

type = "Patent",

note = "WO2004099780; G06F 19/ 20 A N",

}

TY - PAT

T1 - IMMUNOASSAYS FOR THE DETECTION OF UROKINASE RECEPTOR FORMS

AU - Piironen, Timo

AU - Hoeyer-Hansen,, Gunilla

AU - Bruenner,, Nils

AU - Ploug,, Michael

AU - List, Karin

AU - Laursen,, Birgitte

AU - Danoe,, Keld

AU - Liljas,, Hans

AU - Haese, Alexander

AU - Hartwig,, Huland

AU - Toernblom,, Magnus

AU - Gustafsson,, Ove

PY - 2004/11/18

Y1 - 2004/11/18

N2 - The present invention relates to the design of three novel monoclonal uPAR sandwich assays for the specific detection of 1) full-length intact uPAR, 2) full-length intact uPAR and domain 2+3 fragment, and 3) domain 1 fragment of uPAR. The invention further relates to a method combining the detected amounts of uPAR forms in a sample with data indicative of the presence of the cancer disease. The method can be used for staging, prognosis or diagnosis of prostate cancer. Two novel monoclonal antibodies and a kit and immunoassays for detecting at least one uPAR form(s) are also described in the present invention.

AB - The present invention relates to the design of three novel monoclonal uPAR sandwich assays for the specific detection of 1) full-length intact uPAR, 2) full-length intact uPAR and domain 2+3 fragment, and 3) domain 1 fragment of uPAR. The invention further relates to a method combining the detected amounts of uPAR forms in a sample with data indicative of the presence of the cancer disease. The method can be used for staging, prognosis or diagnosis of prostate cancer. Two novel monoclonal antibodies and a kit and immunoassays for detecting at least one uPAR form(s) are also described in the present invention.

M3 - Patent

M1 - WO2004099780

ER -

IMMUNOASSAYS FOR THE DETECTION OF UROKINASE RECEPTOR FORMS

Abstract

UN SDGs

Fingerprint

Cite this